 |
 |

Immunotherapy and Asthma
Robert M. Bogin, MD
University of Colorado Health Sciences Center Denver
JAMA. 1989;262(13):1772.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
 |
 |
To the Editor. —
The article by Ratto et al1 addresses the important issue of cost-effective use of corticosteroids in asthmatic patients. The improvement in airflow in both the orally and intravenously administered methylprednisolone groups is impressive. Their study does, however, raise several issues.
First, should every patient requiring treatment for acute bronchoconstriction receive oral medications? Although the patients in this study were acutely ill, as judged by the forced expiratory volume in 1 second percent predicted, all responded dramatically within 18 hours. If a patient with status asthmaticus should present in a shocklike state, perfusion of peripheral vascular beds, including the gastrointestinal tract, may be altered.2 Absorption of orally administered medications would therefore be expected to be abnormally low, and intravenous drug administration might be expected to be more effective.
Second, what was the inciting event causing the bronchoconstriction? If a bacterial bronchitis was involved in the
. . . [Full Text PDF of this Article]
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|